FATE THERAPEUTICS INC - Common Stock, par value $0.001 per share (FATE)

Historical Holders from Q1 2014 to Q3 2025

Symbol
FATE on Nasdaq
CUSIP
31189P102
Type / Class
Equity / Common Stock, par value $0.001 per share
Shares outstanding
114M
All holders as of September 30, 2025
Q3 2025
Total 13F shares, excl. options
80.5M
Holdings value
$101M
% of all portfolios
0.004%
Grand Portfolio weight change
+0%
Number of holders
137
Number of buys
64
Number of sells
-53
Average Value change %
+0%
Average buys %
+0.004%
Average sells %
0%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of FATE THERAPEUTICS INC - Common Stock, par value $0.001 per share (FATE)

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Redmile Group, LLC 14.9% 0% $25.1M $175K 17.9M +0.7% Redmile Group, LLC Jul 2, 2025
VANGUARD GROUP INC 7.64% $9.82M 8.77M The Vanguard Group Jun 30, 2025
BlackRock, Inc. 6.9% $10.6M 7.85M BlackRock, Inc. Mar 31, 2025
GOLDMAN SACHS GROUP INC 2% -77.1% $2.55M -$6.96M 2.27M -73.2% THE GOLDMAN SACHS GROUP, INC. Jun 30, 2025
Schonfeld Strategic Advisors LLC 0.82% -85.4% $1.05M -$7.68M 938K -88% Schonfeld Strategic Advisors LLC Jun 30, 2025

Institutional Holders of FATE THERAPEUTICS INC - Common Stock, par value $0.001 per share (FATE)

Period Reported Shares, Excl. Options Value, Excl. Options Change Price Investors
2025 Q3 80.5M $101M +$1.89M $1.26 137
2025 Q2 79.6M $88.8M -$17.6M $1.12 136
2025 Q1 96.5M $76.2M -$16.2M $0.79 127
2024 Q4 101M $166M -$49.3M $1.65 154
2024 Q3 115M $401M -$26.3M $3.50 157
2024 Q2 122M $401M -$37.7M $3.28 175
2024 Q1 123M $903M +$226M $7.34 161
2023 Q4 95.3M $356M -$5.13M $3.74 151
2023 Q3 95.7M $203M -$42.2M $2.12 162
2023 Q2 109M $519M -$18.4M $4.76 182
2023 Q1 113M $641M -$48M $5.70 175
2022 Q4 105M $1.06B -$72.2M $10.09 219
2022 Q3 108M $2.41B -$51.5M $22.41 225
2022 Q2 109M $2.68B +$198M $24.78 212
2022 Q1 101M $3.92B +$154M $38.77 236
2021 Q4 96.5M $5.64B +$10.5M $58.51 240
2021 Q3 95.7M $5.67B +$32.9M $59.27 255
2021 Q2 94.4M $8.19B +$63.5M $86.79 264
2021 Q1 93.7M $7.73B +$547M $82.45 250
2020 Q4 87.4M $7.95B -$86.9M $90.93 249
2020 Q3 87.8M $3.51B +$84.9M $39.97 212
2020 Q2 85.9M $2.95B +$357M $34.31 200
2020 Q1 75.6M $1.68B +$78.8M $22.21 154
2019 Q4 72.2M $1.41B -$18.7M $19.57 145
2019 Q3 73.8M $1.15B +$162M $15.53 147
2019 Q2 63.2M $1.28B +$56.7M $20.30 134
2019 Q1 60.8M $1.07B +$24.9M $17.57 122
2018 Q4 59.4M $762M +$32.6M $12.83 121
2018 Q3 54.8M $893M +$194M $16.29 117
2018 Q2 43M $488M +$35.3M $11.34 103
2018 Q1 39.4M $385M +$45.1M $9.76 87
2017 Q4 35.3M $216M +$67.1M $6.11 78
2017 Q3 25.4M $101M -$4.5M $3.96 71
2017 Q2 26.6M $86.2M +$4.85M $3.24 57
2017 Q1 25M $114M +$9.09M $4.55 51
2016 Q4 23.1M $57.9M +$7.41M $2.51 33
2016 Q3 19.5M $60.8M +$17.1M $3.12 36
2016 Q2 14.1M $23.9M -$3.09M $1.70 37
2016 Q1 15.8M $28.4M -$9.46M $1.80 43
2015 Q4 18.6M $62.7M -$726K $3.37 51
2015 Q3 18.3M $97.8M +$1.75M $5.33 42
2015 Q2 18M $117M +$48M $6.47 37
2015 Q1 10.6M $51.9M +$1.63M $4.89 25
2014 Q4 10.3M $51.7M -$3.44K $5.02 23
2014 Q3 10.3M $52.6M +$2.08M $5.10 22
2014 Q2 9.85M $62.4M +$1.72M $6.31 21
2014 Q1 9.56M $92.8M +$30.7M $9.74 21